GRANT AGREEMENT

Parties to this agreement:

Danmarks Bløderforening
Att: Karen Binger Holm
Blekinge Boulevard 2
2630 Taastrup

CVR: 11802990
("Recipient")

Novo Nordisk Denmark A/S
Att.: Søren Beicker Sørensen
Kay Fiskers Plads 10, 7 floor
2300 København S
CVR No. 38180045

("Novo Nordisk")

1. Summary

1.1 Recipient's request for support. The appendix titled "Recipient's request for support" details the specifics of the Recipient's activity(ies) ("the Activity") supported by the grant and purpose of the Activity. Novo Nordisk has decided to support the recipient's request as part of its commitment to advance healthcare and science.

Title of Activity	Nordic Baltic Meeting 20-22nd March 2026
Purpose of the Activity	The recipient shall use the grant only for the healthcare-related purpose of holding yearly meeting for Nordic/Baltic hemophilia societies, held in Copenhagen. *The recipient's purpose must not involve promotion of any pharmaceutical product.*
Grant amount	Novo Nordisk will provide 32 592 DKK, including added tax if applicable, to support the Recipient's request. Novo Nordisk will not make any non-financial transfers of value.
Agreement Duration	This agreement starts on the last signature date below and expires after all obligations are fulfilled, unless terminated earlier.

2. Recipient's Duties

2.1 Compliance with law and ethics. The Recipient shall comply with all applicable laws, rules, regulations, and professional standards, including those related to ethical business practices, bribery and corruption, among others. The Recipient will hold Novo Nordisk harmless against any claim or suit that arises in relation to any deviation from the above mentioned that is not due to any act or omission by Novo Nordisk.

2.2 Carry out the Activity with proper conduct. The Recipient shall carry out the Activity independently and without Novo Nordisk influence, and in compliance with Novo Nordisk standards and industry codes such as IFPMA, EFPIA and ENLI (Etisk Nævn for Lægemiddelindustrien). Such proper conduct of the Activity includes, but is not limited to:

No use of funds for entertainment	Do not use the grant for leisure or social activities
No use of product names	Do not use trade and advertising names of medicinal products in any content or materials used for the Activity
Select qualified participants	Apply appropriate criteria to select participants in the Activity, including that any speakers, facilitators, and chairpersons are experts in the professional fields relevant to the Activity

Reasonable payment	If grant is used to provide payments to third parties, apply a reasonable rate, including following Fair Market Value for any payments to Healthcare Professionals (hereinafter refer to as 'HCPs') and patients. Under this agreement, funding from Novo Nordisk will not cover any honoraria or related honoraria expenses such as travel and accommodation for HCPs.
Reasonable choice of venue	Hold activities in a location suitable for business meetings with modest hospitality in line with the hospitality limits set out in ENLI's Patient Organisation Code
Reasonable travel	If grant is used for Activity-related travel, carry out within reasonable time and cost
Transparency about support towards participants	The invitation for the event must clearly state that the event is being supported by one or more pharmaceutical companies.
Acknowledgment of obligations towards ENLI	The Recipient acknowledges that Novo Nordisk must report the grant to ENLI (Etisk Nævn for Lægemiddelindustrien) in accordance with ENLI's Patient Organisation Code.
Acknowledgement of obligations towards Danish Medicines Agency	If Danish doctors, dentists or pharmacists are affiliated with the activity and receive honorarium from the support provided by Novo Nordisk these persons must be informed about their obligation to report this affiliation to Danish Medicines Agency. The Recipient undertakes to fulfil this information duty and to give Novo Nordisk the following information: Name, authorisation ID, workplace, home address, affiliation start date, affiliation end date. Novo Nordisk must also report this information to the Danish Medicines Agency.

2.3 Internal approvals. The Recipient shall obtain all necessary approvals related to the receipt of the grant.

2.4 Provide documentation within 1 month. The Recipient shall provide Novo Nordisk with documentation that the grant was used for its intended purpose, within 1 month of completion of the Activity. Novo Nordisk may request additional detailed documentation as needed.

2.5 Inform Novo Nordisk of changes. The Recipient shall inform Novo Nordisk of any changes affecting the request for support. Novo Nordisk may increase, decrease, withdraw or require full or partial repayment of the grant as a result of the changes. In the case of repayment, the Recipient shall refund Novo Nordisk the requested amount within 14 days.

2.6 Refund unspent amounts. The Recipient shall refund Novo Nordisk any amounts not spent for the requested purposes, within 14 days after complete documentation of the Activity is provided.

2.7 Disclose Novo Nordisk as grant provider. The Recipient shall mention Novo Nordisk as the provider of the grant in educational materials developed through the grant, as well as in any public communications or advertising related to the Activity.

2.8 Required public disclosures. Novo Nordisk will publish information relating to this grant on Novo Nordisk's website (www.novonordisk.dk). According to Danish regulation Novo Nordisk may in addition make this Grant Agreement publicly available. The Recipient shall provide to Novo Nordisk upon request all information reasonably required for Novo Nordisk's compliance with legal and/or regulatory requirements for contracting, tracking and disclosing transfer of values (ToVs) to the Recipient

The Recipient will publish information on the grant on the Recipient's webpage. The information includes the grants amount and, if applicable, any in kind transfer, cf. the Danish Pharmaceutical Promotional Act (Reklamebekendtgørelsen) § 21. The information must be available on the Recipient's webpage no later than one (1) month after the Recipient received the Grant. The information must be publicly available for at least two (2) years.

2.9 Do not use Novo Nordisk branding without approval. The Recipient may not use Novo Nordisk's logo, trademarks or other corporate identity marks or materials without written approval of the use from Novo Nordisk.

2.10 Allow Novo Nordisk to use Recipient's logo. The Recipient permits Novo Nordisk to use the Recipient's logo, trademarks or other corporate identity marks in any public communications or advertising related to Novo Nordisk's grant.

3. Payment and Invoice Requirements

3.1 Payment after receipt of invoice. Novo Nordisk will send payment after receipt of invoice to the Recipient's bank account via electronic transfer within 30 days of receiving a complete invoice. Send completed PDF invoice to: AP-Novo-Repas@novonordisk.com. Include the below information on the invoice:

- Recipient name and address
- Bank account for electronic payment: Account holder name, account number (IBAN), bank name and address, routing number or code (SWIFT/BIC in EU, ABA/ACH in USA)
- Date of invoice
- The Title of Activity and dates of activities covered by the invoice
- Grant amount payable
- VAT or other tax amount payable (include separately from payment amount)
- Name of Novo Nordisk entity and address as stated in the introduction of this Agreement
- Novo Nordisk recipient of invoice as included below:

Name of Novo Nordisk invoice recipient Søren Beicker Sørensen (SBSB)

4. Other Terms and Conditions

4.1 Disclosure of Transfers of Value. To comply with applicable transparency requirements, Novo Nordisk will collect and may disclose personal information, transfers of value and details of its payment to Healthcare Professionals ("HCPs") and Healthcare Organizations ("HCOs"). In addition to the payment amount, such disclosure may also include: Name, address, contact details, nature of relationship with Novo Nordisk, tax number or unique identifier.

4.2 No conflict of interest. Recipient states it is not aware of any conflict of interest related to its acceptance of the grant and shall promptly inform Novo Nordisk if such conflict of interest is discovered.

4.3 Compliance hotline. The Recipient can report suspected misconduct through the Novo Nordisk compliance hotline. Information about using the hotline and examples of what to report can be found at Report suspected misconduct (novonordisk.com).

4.4 No incentive to prescribe or recommend. The payments made by Novo Nordisk indicate no incentive or obligation for the Recipient to prescribe, recommend or otherwise support Novo Nordisk's products or services.

4.5 Termination for breach. Either party may terminate this contract immediately upon material breach by the other party.

4.6 Governing Law and Dispute Resolution. The laws of Denmark govern this agreement, disregarding choice of law rules. If a dispute cannot be settled by negotiation between parties, it will be settled by the ordinary courts in that country.

5. **Attachments**

The following attachments are part of this agreement :

Attachment A: Recipient's request for support incl. budget and program

6. Agreed to and Accepted by:

Date: 10 marts 2026

On behalf of Recipient: Signed by: Karen Binger Holm 46A0A742616D4F7...

Name: Karen Binger Holm

Title: Sekretariatsleder

Date: 06 marts 2026

On behalf of Novo Nordisk: DocuSigned by: Søren Beicker Sørensen 80BA49E04E66467...

Name: Søren Beicker Sørensen

Title: Sr Public Affairs Manager

Appendix A: Recipient's Request for Support

1. Copy of the Recipient's grant request incl budget

Danmarks Bløderforening
Blekinge Boulevard 2
2630 Taastrup
Tlf. 3314 5505
www.bloderforeningen.dk

Novo Nordisk Danmark
Att.: Christian Klyver Tikkanen
ctik@novonordisk.com

D. 5. januar 2026

Ansøgning om støtte til Nordisk møde i København d. 20-22. marts 2026

Med denne ansøgning vil Danmarks Bløderforening søge Novo Nordisk om støtte til afholdelse af det årlige møde for bløderforeninger i Norden og Baltikum.

Mødet afholdes d. 20-22. marts 2026 i København på Scandic Kødbyen. Danske bløderlæger og sygeplejersker og repræsentanter fra medicinalindustrien inviteres også til at deltage i det faglige program lørdag d. d. 21. marts.

For mennesker med sjældne sygdomme er det helt afgørende, at viden og erfaringer om både behandling og livskvalitet kan deles på tværs af landegrænser, det gælde for såvel patientforeninger som for behandlingsfaglige miljøer. De deltagende patientforeninger, i det årlige møde, varetager interesserne for patienter med blødersygdomme som hæmofili og von Willebrands sygdom. Der er tale om sjældne sygdomme, og derfor er foreningerne små. Den svenske forening med ca. 1.100 medlemmer er den største, mens den islandske med ca. 70 medlemmer er den mindste. Da de nordiske og til dels baltiske sundhedssystemer og sociale velfærdsmodeller er ret ens, er der mange emner, som er relevante at diskutere på tværs, og hvor vi har stor gavn af at samarbejde.

Udover foreningsrepræsentanter inviteres også unge-repræsentanter fra de nordiske lande. Der vil være et delvist separat mødeprogram for unge-gruppen, som blandt andet vil handle om forberedelse af den kommende nordisk/baltiske ungecamp, som afholdes til juni i Norge. Ved at styrke netværket mellem vores nordiske og baltiske foreninger, og særligt sikre at den unge generation også knytter bånd på tværs af regionen, understøtter vi fundamentet for fortsat samarbejde og samhørighed.

Programmet er stadig under udarbejdelse, men ud over at give mulighed for at dele erfaringer og eksempler på god praksis og modelaktiviteter på tværs af foreningerne, så ønsker Danmarks Bløderforening med mødet også at sætte fokus på følgende emner:

Health Technology Assessment: Der sker i øjeblikket store ændringer på grund af ny EU-lovgivning, der vil flytte en del af ansvaret for vurdering af ny medicin fra medlemslandene til det Europæiske Lægemiddelagentur. Danmark er det eneste land, som har patientrepræsentanter inddraget i HTA-processer. Derfor er vi som patientforeninger bekymrede for, om patientens stemme fortsat bliver hørt, når mere af beslutningskompetencen flyttes til det overnationale niveau.

Forsyningssikkerhed: Blødermedicin fremstilles på få højt specialiserede produktionsanlæg med lange forsyningskæder. I en verden med geopolitiske spændinger og forhindringer for frihandel, hvor sårbare er vi så?

Danmarks Bløderforening
Blekinge Boulevard 2
2630 Taastrup
Tlf. 3314 5505
www.bloderforeningen.dk

Anvendelse af AI: Kunstig intelligens vinder i øjeblikket indpas i mange områder af samfundet. Hvilke muligheder giver det os som patienter og som foreninger? Og hvad kommer det til at betyde for vores informationsarbejde?

Det samlede budget for mødet er i alt 162.959 kr. Der søges om støtte fra Novo Nordisk på 32.592 kr. Se budget nedenfor. Ved støtte vil firmalogo fremgå af endelig invitation og program ligesom roll-up og op til to materialer kan udstilles i mødeområdet.

Udgifter	**Beløb DKK**
Ophold	63.780
Mødelokale	7.560
Mødepakke, fredag	12.300
Mødepakke, lørdag	37.344
Mødepakke, søndag	20.400
Vand til måltider	3.075
Honorar, oplægsholdere	15.000
Transportudgifter, oplægsholdere	3.500
Total	**162.959**
Notat	
Hotel Scandic Kødbyen, København	
30 enkeltværelser, fre-søn inkl. morgenmad á 2.126 kr.	
Fredag, aftenmøde - 30 deltagere á 410 kr.	
Lørdag, heldagsmøde - 48 deltagere á 778 kr.	
Søndag, halvdagsmøde - 30 deltagere á 680 kr.	

AI støtte til dette formål modtages med tak. Hvis der er spørgsmål til ansøgningen, står jeg meget gerne til rådighed.

Venlig hilsen

Karen Binger Holm
Sekretariatsleder

---

2. Activity program

Nordic Baltic Meeting 2026

PROGRAMME

20-22 March 2026

Scandic Kødbyen, Copenhagen

Friday

18:00 **Welcome and Introduction**

18:15 **Status on Management of Bleeding Disorders in Denmark**
Gene therapy, sub-cutaneous treatments, what is on the horizon? *Speaker: Eva Funding, Consultant, Head of section, Hemophilia and Benign Hematology, Department of Hematology, National University hospital Rigshospitalet*

19:00 **Dinner at the hotel**

Saturday

09:00 **Introduction to Today's Programme**

09:15 **Medicine Supply Chains in a Changing World**
Political shifts challenge free trade. Treatments are becoming more diverse. The EU list of critical medicines does not include most of the treatment products that are currently used for bleeding disorders. How well prepared are we for a crisis and how can we as patient organisations contribute? *Speaker: (tbc)*

10:00 **Coffee break**

10:15 **Health Technology Assessment**
EU's new HTA regulation has moved part of the HTA process from the national level to the EU level. The Nordic HTA agencies have started joint assessments for some new medicines. How do we ensure the patient's perspective is heard? *Speaker: Jørgen Schøler Kristensen, DMSci, former chairman of the Danish Medicines Council*

11:15 **Sharing is caring: Update from Each Organisation**
10-minute update from each country – current challenges, active projects and what is the outlook?

12:45 **Lunch**

13:45 **Keynote: AI in the World of Bleeding Disorders**
Part1: AI is entering many parts of our lives including our health system. What are the learnings so for and what are the potentials? *Speaker: Anders Christian Riis-Jensen, AI Team Leader and AI Architect, Capital Region*

Nordic Welfare Centre

Danmarks Bløderforening

Part 2: In a world where ChatGPT and other language models become the place where many people search for information, how can AI support and challenge doctors and patients? *Speaker: Anton von Hofacker, Medical Doctor*

15:15 **Coffee Break**

15:45 Part 3: How do we as patient organisations remain relevant and ensure patients have access to safe and validated information?

Sharing is Caring: Group Work on AI
Discussion in groups on how AI can help us in patient organisations and what threats we see. Plenary presentations at the end.

16.45: **Free Time**

19.00 **Dinner**

Sunday

09:00 **Update on the Nordic Youth Camp**
Nicolai (DK) and Rebecca (NO) present current state of planning.

09:30 **Tips and Tricks for a Successful Camp**
Tem (DK) has lead the Danish summer camp for more than 20 years and continued to set records for participants. What are the elements of a successful camp? How do you bring the right team together? Will the camps stay relevant with the changes in treatment?

10:30 **Coffee Break**

11:00 **Hot topics + Reflections on Weekend**

11:30 **Wrap up and Next Year**
Summing up what we have learned and what we take home to work on.
Discussion on hosting next year's meeting and going forward.

12:00 **Lunch To-Go or To-Stay**

Nordic Welfare Centre

Danmarks Bløderforening